Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QVA149 vs Placebo in COPD (MOVE)
NCT01996319Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2014
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of indacaterol + glycopyrronium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Novartis. Primary endpoints: Peak Inspiratory Capacity at Day 57 and Average Physical Activity Level at Day 57. Started Apr 2014; status: completed.
02
Drugs
indacaterol + glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01996319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01996319.